A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2a Study of the Effects of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
Latest Information Update: 11 Jan 2024
Price :
$35 *
At a glance
- Drugs HU 6 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Rivus Pharmaceuticals
- 05 Jan 2024 Status changed from recruiting to withdrawn prior to enrolment. The protocol was redirected by the FDA to another division and will be resubmitted at a future date.
- 05 Dec 2023 Status changed from not yet recruiting to recruiting.
- 31 Oct 2023 New trial record